Urology · 5-alpha reductase inhibitorRegulatory Approvalcommercialnear-term

Teva's Finasteride ANDA076511 Receives Abbreviated Approval from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:30:52 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's Abbreviated Approval for Finasteride introduces a generic competitor to the market, which could significantly impact pricing and market share dynamics. Pharma strategy teams must evaluate the implications for their branded products and adjust strategies accordingly. Regulatory context from FDA (FDA AP — FINASTERIDE (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for Finasteride products. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Urology · 5-alpha reductase inhibitor, 5 regulatory and 4 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo). This approval allows Teva to enter the market with a generic version of Finasteride, increasing competition against branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FINASTERIDE (SUPPL) (FDA). Entity match (teva); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not introduce new regulatory challenges for the industry.

Key Risks

Clinical risk from ClinicalTrials.gov (Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment) could weigh on Teva through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Teva's generic Finasteride may lead to price erosion for existing branded products, affecting revenue and market positioning.
Upside for Teva may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for Teva may improve if PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Finasteride products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry date and any potential challenges from branded competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With Bruton's Tyrosine Kinase Inhibitor and B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pacritinib, Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplas
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Sandoz Receives FDA Approval for Liraglutide ANDA212972
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment

Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Finasteride
branded competitors

Commercial impact

medium

The entry of Teva's generic Finasteride may lead to price erosion for existing branded products, affecting revenue and market positioning.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not introduce new regulatory challenges for the industry.

What to watch

Monitor market entry date and any potential challenges from branded competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.